Citigroup’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-100
Closed -$3K 7396
2020
Q4
$3K Hold
100
﹤0.01% 7213
2020
Q3
$2K Hold
100
﹤0.01% 7322
2020
Q2
$2K Hold
100
﹤0.01% 7427
2020
Q1
$1K Sell
100
-2,400
-96% -$36.1K ﹤0.01% 7521
2019
Q4
$36K Hold
2,500
﹤0.01% 6590
2019
Q3
$29K Buy
+2,500
New +$41.3K ﹤0.01% 6510
2019
Q2
Sell
-1,200
Closed -$27K 7861
2019
Q1
$27K Sell
1,200
-5,600
-82% -$124K ﹤0.01% 6796
2018
Q4
$154K Buy
6,800
+6,700
+6,700% +$167K ﹤0.01% 5273
2018
Q3
$3K Buy
+100
New +$2.86K ﹤0.01% 7576
2018
Q2
Sell
-2,000
Closed -$45K 7743
2018
Q1
$45K Sell
2,000
-200
-9% -$4.76K ﹤0.01% 6243
2017
Q4
$46K Sell
2,200
-100
-4% -$2.29K ﹤0.01% 6242
2017
Q3
$57K Hold
2,300
﹤0.01% 5928
2017
Q2
$45K Sell
2,300
-1,300
-36% -$23.6K ﹤0.01% 5862
2017
Q1
$66K Sell
3,600
-800
-18% -$15.6K ﹤0.01% 5513
2016
Q4
$83K Buy
4,400
+4,200
+2,100% +$85.9K ﹤0.01% 5883
2016
Q3
$4K Buy
+200
New +$3.81K ﹤0.01% 6829

Other funds holding TVTX

Citigroup's TVTX Position: Q2 2026 in Review

Citigroup increased its Travere Therapeutics (TVTX) stake by 324% in Q2 2026, buying an estimated $3.9M and bringing the position to 115,045 shares worth $6.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

Citigroup first reported a position in TVTX in Q1 2014 and has held it in 50 quarters since. The position peaked at $8.14M in Q1 2023. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Citigroup held 115,045 shares of Travere Therapeutics worth $6.54M as of Q2 2026.
  • Citigroup bought 87,914 Travere Therapeutics shares in Q2 2026, an estimated $3.9M.
  • Travere Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1917 holding.
  • Citigroup first reported a position in Travere Therapeutics in Q1 2014 and has held it in 50 quarters since.
  • Citigroup's Travere Therapeutics position peaked at $8.14M in Q1 2023.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.